Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Ultra-rapid Opiate Detoxification Using Deep Sedation and Prior Oral Buprenorphine Preparation.

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2009 by Assaf-Harofeh Medical Center.
Recruitment status was  Not yet recruiting
Information provided by:
Assaf-Harofeh Medical Center Identifier:
First received: November 4, 2009
Last updated: NA
Last verified: November 2009
History: No changes posted

The methods of detoxification under general anesthesia have been criticized because of limited data on safety and long-term follow-up. Premedication with buprenorphine has been advocated to improve safety. In current study we want to evaluate the importance of buprenorphine preparation in rapid opioid detoxification process, under general anesthesia.

Opioid Addiction

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective

Resource links provided by NLM:

Further study details as provided by Assaf-Harofeh Medical Center:

Estimated Enrollment: 40
Study Start Date: December 2009
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
without buprenorphine preparation
with buprenorphine preparation


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

All opioid addicted patients who wants to undergo rapid detoxification under general anesthesia.


Inclusion Criteria:

  • Opioid addiction

Exclusion Criteria:

  • Age < 18 Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01008072

Contact: Murat Bahar, MD 97289778080

Anesthesiology department, Assaf-Harofeh MC Not yet recruiting
Beer-Yaakov, Zrifin, Israel, 70300
Contact: Murat Bahar, MD    97289778080   
Principal Investigator: Murat Bahar, MD         
Sponsors and Collaborators
Assaf-Harofeh Medical Center
  More Information

No publications provided

Responsible Party: Murat Bahar, Assaf-Harofeh MC Identifier: NCT01008072     History of Changes
Other Study ID Numbers: 173/09
Study First Received: November 4, 2009
Last Updated: November 4, 2009
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Analgesics, Opioid
Central Nervous System Agents
Central Nervous System Depressants
Narcotic Antagonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on November 25, 2014